Broker Revenue Forecasts For Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Are Surging Higher

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased their revenue numbers, with a view that Arcturus Therapeutics Holdings will make substantially more sales than they'd previously expected.

Following the upgrade, the consensus from eight analysts covering Arcturus Therapeutics Holdings is for revenues of US$153m in 2023, implying a substantial 46% decline in sales compared to the last 12 months. Before the latest update, the analysts were foreseeing US$87m of revenue in 2023. The consensus has definitely become more optimistic, showing a considerable lift to revenue forecasts.

View our latest analysis for Arcturus Therapeutics Holdings

These estimates are interesting, but it can be useful to paint some more broad strokes when seeing how forecasts compare, both to the Arcturus Therapeutics Holdings' past performance and to peers in the same industry. We would highlight that sales are expected to reverse, with a forecast 56% annualised revenue decline to the end of 2023. That is a notable change from historical growth of 63% over the last five years. Compare this with our data, which suggests that other companies in the same industry are, in aggregate, expected to see their revenue grow 20% per year. So although its revenues are forecast to shrink, this cloud does not come with a silver lining - Arcturus Therapeutics Holdings is expected to lag the wider industry.

The Bottom Line

The most important thing to take away from this upgrade is that analysts lifted their revenue estimates for this year. They're also anticipating slower revenue growth than the wider market. Seeing the dramatic upgrade to this year's forecasts, it might be time to take another look at Arcturus Therapeutics Holdings.

Of course, there's always more to the story. At least one of Arcturus Therapeutics Holdings' eight analysts has provided estimates out to 2025, which can be seen for free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.